October 19, 2016 / 15:19 IST
Centrum has come out with its second quarter (July-September) earnings estimates for the Pharmaceuticals sector. The brokerage house expects
Dr. Reddy's Labs to report net profit at Rs 170.5 crore, up 11.1 percent quarter-on-quarter.Net Sales are expected to increase by 2.9 percent Q-o-Q (down 16.9 percent Y-o-Y) to Rs 3316 crore, according to Centrum.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 11.2 percent Q-o-Q (down 51.4 percent Y-o-Y) to Rs 434 crore.
Centrum's report on Dr. Reddy's LabsWe expect Dr. Reddy’s Labs (DRL) to report revenue decline of 17% YoY and revenue growth of 3% QoQ to Rs33.16bn due to higher base and absence of new launches due to three of its facilities under US FDA scanner. Its global generic business (82% of revenues) is expected to decline by 17% YoY and grow by 3% QoQ to Rs27.35bn due to expected drop in revenues in US , Europe and emerging markets. We expect DRL’s PSAI business (14% of revenues) to decline by 20% YoY and remain flat on QoQ to Rs4.71bn.Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
